Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.33549/physiolres.934647 http://scihub22266oqcxt.onion/10.33549/physiolres.934647 33728925!8820511!33728925     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Physiol+Res 2021 ; 70 (1): 111-115 Nephropedia Template TP {{tp|p=33728925|t=2021. CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects |pdf=|usr=}}{{33728925}} gab.com Text CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects JO: Physiol Res http://www.kidney.de/pget.php?&tw=1&pmid=33728925 #FOAvip Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5Delta32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5?32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5Delta32 carriers in SARS-CoV-2-positive/COVID-19-asympto-matic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5?32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection. Twit Text FOAVip CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects ????Physiol Res http://www.kidney.de/pget.php?&tw=1&pmid=33728925 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33728925 #FOAvip English Wikipedia <ref>{{Cite pmid|33728925}}</ref> CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects #MMPMID33728925 Hubacek JA; Dusek L; Majek O; Adamek V; Cervinkova T; Dlouha D; Pavel J; Adamkova V Physiol Res 2021[Mar]; 70 (1): 111-115 PMID33728925show ga Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5Delta32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5?32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5Delta32 carriers in SARS-CoV-2-positive/COVID-19-asympto-matic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5?32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection. |*Sequence Deletion[MESH] |COVID-19/diagnosis/*genetics/virology[MESH] |Case-Control Studies[MESH] |Czech Republic[MESH] |Gene Frequency[MESH] |Genetic Association Studies[MESH] |Genetic Predisposition to Disease[MESH] |Humans[MESH] |Phenotype[MESH] |Protective Factors[MESH] |Receptors, CCR5/*genetics[MESH] |Risk Assessment[MESH] |Risk Factors[MESH]CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-(epmc).pdf DeepDyve Pubget Overpricing